[Adefovir in reactivation of chemotherapy-induced hepatitis B in an anti-Hbc-positive patient].
Castelló Miralles
Inmaculada
I
Del Val Antoñana
Adolfo
A
Muñoz Vicente
Margarita
M
Moreno-Osset
Eduardo
E
D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D000998:Antiviral Agents / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects; D003606:Dacarbazine / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D017809:Fatal Outcome; D005260:Female; D006515:Hepatitis B virus / Q000187:drug effects / Q000502:physiology; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D063065:Organophosphonates / Q000627:therapeutic use*; D017096:Prion Diseases / Q000209:etiology; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects; D014775:Virus Activation
D000998:Antiviral Agents; D063065:Organophosphonates; D001761:Bleomycin; D014747:Vinblastine; C053001:adefovir; D003606:Dacarbazine; D004317:Doxorubicin; D000225:Adenine